Drug name
Last update: Jul 2026Glecaprevir Pibrentasvir LA injection
Developer(s)
Drug information
Not provided
Glecaprevir Pibrentasvir LAI
Not provided
Small molecule
antivirals
Not provided
Unknown
Unknown
Therapeutic area(s)
- HCV
- Treatment
Administration route
Subcutaneous, Intramuscular, Route of administration of the injectable formulation is being determined in the clinical program
Associated long-acting platforms
Aqueous drug particle suspension
Use of drug
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- To be determined
- Other/Variable/Unknown : To be determined based on clinical development
- Once
To be determined
Dosage
Not provided
Not provided
Not provided
Not provided
Not provided
Formulations
Compare
Glecaprevir (G)
Pibrentasvir (P)
Associated technologies
Not provided
Comment & Information
Developer(s)
Tandem Nano
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients
No proprietary excipient used
No novel excipient or existing excipient used
No residual solvent used
Delivery device(s)
No delivery device
long acting injectable liquid formulations comprising an aqueous dispersion of microparticles of glecaprevir and/or pibrentasvir stabilised by a first excipient and a second excipient.
The present invention relates to long acting injectable liquid formulations comprising an aqueous dispersion of microparticles of glecaprevir and/or pibrentasvir stabilised by a first excipient and a second excipient. The present invention also relates to solid compositions which may be used as a precursor for the long acting injectable formulations, aqueous dispersions, microneedle arrays, implantable rods, and pharmaceutical compositions, methods of producing such long acting injectable formulations, and medical uses for such formulations and methods of treatment using such formulations.
WO2023052776
Formulation
University of Liverpool
Not provided
September 29, 2042
Pending in EP, IN, US and CN
Publications
There are no publication
Additional documents
No documents were uploaded
Collaborate for development
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Share technical information for match-making assessment
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
Work with MPP to expand access in LMICs
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing